Whittier Trust Co. Purchases 257 Shares of Boston Scientific Co. (NYSE:BSX)

Whittier Trust Co. increased its holdings in Boston Scientific Co. (NYSE:BSX) by 4.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,101 shares of the medical equipment provider’s stock after purchasing an additional 257 shares during the period. Whittier Trust Co.’s holdings in Boston Scientific were worth $545,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Advisors Asset Management Inc. raised its position in shares of Boston Scientific by 21.3% during the 3rd quarter. Advisors Asset Management Inc. now owns 24,060 shares of the medical equipment provider’s stock valued at $2,016,000 after buying an additional 4,233 shares in the last quarter. Citizens Financial Group Inc. RI raised its holdings in Boston Scientific by 41.4% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 5,039 shares of the medical equipment provider’s stock valued at $422,000 after buying an additional 1,475 shares during the period. 49 Wealth Management LLC bought a new stake in Boston Scientific in the third quarter worth $208,000. Icon Wealth Advisors LLC purchased a new position in Boston Scientific during the third quarter worth $1,104,000. Finally, Nwam LLC bought a new position in Boston Scientific during the third quarter valued at $294,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Argus set a $130.00 price target on shares of Boston Scientific in a research note on Tuesday, February 18th. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a report on Monday, March 3rd. Citigroup boosted their price objective on Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a report on Thursday, February 6th. Stifel Nicolaus increased their target price on Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. Finally, Morgan Stanley boosted their target price on shares of Boston Scientific from $100.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. Two investment analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $108.91.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CFO Daniel J. Brennan sold 67,333 shares of the stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the sale, the chief financial officer now directly owns 225,808 shares of the company’s stock, valued at approximately $23,764,033.92. This trade represents a 22.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the transaction, the executive vice president now directly owns 5,502 shares of the company’s stock, valued at approximately $560,103.60. This trade represents a 75.88 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 137,302 shares of company stock worth $14,319,269 over the last 90 days. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Trading Down 0.8 %

Shares of NYSE:BSX opened at $100.66 on Friday. The business’s 50-day moving average is $101.68 and its 200 day moving average is $92.43. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a 1 year low of $66.80 and a 1 year high of $107.17. The firm has a market capitalization of $148.55 billion, a P/E ratio of 80.53, a P/E/G ratio of 2.79 and a beta of 0.77.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, research analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.